TIME TITLE SPEAKER 8:00–8:30 Networking, Registration   8:30–8:35 Opening Speech Shidong Jia (Predicine) Session 1 China for Global: Biomarker & CDx Solutions for Clinical Trials  Chair: Chunxia Su (Shanghai Pulmonary Hospital) 8:35–8:55 Integrated molecular analysis of NSCLC brain metastasis tissue and multimodal ctDNA reveals distinct signatures of patient outcomes Darin Dolezel (Yale) 8:55–9:15 Advancing NMIBC...

   

   

Predicine’s Liquid Biopsy Next-Generation Sequencing (NGS) Assay is Granted Breakthrough Device Designation by U.S. Food and Drug Administration   SILICON VALLEY, Calif., (September 20, 2022) – Predicine, Inc., a global molecular insights company committed to advancing precision medicine in oncology and infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough...

SILICON VALLEY, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) — Predicine, Inc., a global molecular insights company, announced today that it will present four posters at the ESMO conference being held September 9-13, 2022, in Paris, France. Predicine’s liquid biopsy portfolio includes high performing assays that provide translational insights to aid in potential cancer therapeutic strategies....

SILICON VALLEY, Calif., Aug 09, 2022 / Predicine, Inc., a global molecular insights company, has launched its CE-marked PredicineCARE™ for genomic profiling in blood and urine. The PredicineCARETM cell free DNA (cfDNA) assay is a targeted Next-Generation Sequencing (NGS) assay for the detection of single nucleotide variants (SNVs), insertions and deletions (Indels), DNA re-arrangements (fusions)...